Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bogdan, M.
Right arrow Articles by Lindenbaum, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bogdan, M.
Right arrow Articles by Lindenbaum, A.
Thorax 1998;53:1059-1062 ( December )

Urinary cGMP concentrations in severe primary pulmonary hypertension

Miron Bogdan, Marc Humbert, Jeanne Francoual, Catherine Claise, Pierre Duroux, Gérald Simonneau, Albert Lindenbaum

Services de Pneumologie, Réanimation Respiratoire et Biochimie, UPRES "Maladie Vasculaires Pulmonaires", Hôpital Antoine Béclère, Clamart, France

Correspondence to: Dr M Humbert, Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine Béclère, 157 Rue de la Porte de Trivaux, 92140 Clamart, France.

Received 26 January 1998; Returned to authors 1 April 1998; Revised version received 26 May 1998; Accepted for publication 9 July 1998

BACKGROUND---Prognostic evaluation of patients with primary pulmonary hypertension (PPH) requires right heart catheterisation. The development of accurate non-invasive methods for monitoring these patients remains an important task. Cyclic guanosine monophosphate (cGMP) is an indicator of the action of natriuretic peptides and nitric oxide on target cells. Plasma and urinary cGMP concentrations are raised in patients with congestive heart failure in whom they correlate closely with haemodynamic parameters and disease severity. The aim of the present study was to determine whether the urinary concentration of cGMP could be used as a non-invasive marker of haemodynamic impairment in patients with severe PPH.
METHODS---Urinary cGMP concentrations were measured in 19 consecutive patients with PPH, seven with acute asthma, and 30 normal healthy controls.
RESULTS---Patients with PPH had higher urinary cGMP concentrations than asthmatic patients or normal healthy controls (p = 0.001). Urinary cGMP concentrations were higher in patients with severe haemodynamic impairment---that is, those with a cardiac index (CI) of =<2 l/min/m2 (p = 0.002)---and urinary cGMP concentrations were inversely correlated with CI (r = -0.69, p = 0.002) and venous oxygen saturation (r = -0.65, p = 0.003).
CONCLUSION---Urinary cGMP concentrations may represent a non-invasive indicator of the haemodynamic status of patients with severe PPH.

Keywords: 3'-5'-cyclic guanosine monophosphate; haemodynamics; pulmonary hypertension

© 1998 by Thorax


This article has been cited by other articles:


Home page
 Eur Respir JHome page
G. Warwick, P. S. Thomas, and D. H. Yates
Biomarkers in pulmonary hypertension
Eur. Respir. J., August 1, 2008; 32(2): 503 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Peacock, R. Naeije, N. Galie, and J.T. Reeves
End points in pulmonary arterial hypertension: the way forward
Eur. Respir. J., June 1, 2004; 23(6): 947 - 953.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Shitrit, D. Bendayan, A. Bar-Gil-Shitrit, M. Huerta, B. Rudensky, G. Fink, and M. R. Kramer
Significance of a Plasma D-dimer Test in Patients With Primary Pulmonary Hypertension
Chest, November 1, 2002; 122(5): 1674 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. M. Hare, G. C. Nguyen, A. F. Massaro, J. M. Drazen, L. W. Stevenson, W. S. Colucci, J. C. Fang, W. Johnson, M. M. Givertz, and C. Lucas
Exhaled nitric oxide: a marker of pulmonary hemodynamics in heart failure
J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1114 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
H.A. Ghofrani, R. Wiedemann, F. Rose, N. Weissmann, R.T. Schermuly, K. Quanz, F. Grimminger, W. Seeger, and H. Olschewski
Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders
Eur. Respir. J., April 1, 2002; 19(4): 664 - 671.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Wiedemann, H. A. Ghofrani, N. Weissmann, R. Schermuly, K. Quanz, F. Grimminger, W. Seeger, and H. Olschewski
Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: Response to iloprost inhalation
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1130 - 1136.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
H. Wilkens, A. Guth, J. Konig, N. Forestier, B. Cremers, B. Hennen, M. Bohm, and G. W. Sybrecht
Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension
Circulation, September 11, 2001; 104(11): 1218 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Archer and S. Rich
Primary Pulmonary Hypertension : A Vascular Biology and Translational Research "Work in Progress"
Circulation, November 28, 2000; 102(22): 2781 - 2791.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Prasad, J. Wilkinson, and M. A. Gatzoulis
Sildenafil in Primary Pulmonary Hypertension
N. Engl. J. Med., November 2, 2000; 343(18): 1342 - 1342.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1998 BMJ Publishing Group Ltd & British Thoracic Society